270 related articles for article (PubMed ID: 10199760)
1. The control on growth hormone release by free fatty acids is maintained in acromegaly.
Lanzi R; Losa M; Mignogna G; Caumo A; Pontiroli AE
J Clin Endocrinol Metab; 1999 Apr; 84(4):1234-8. PubMed ID: 10199760
[TBL] [Abstract][Full Text] [Related]
2. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
[TBL] [Abstract][Full Text] [Related]
3. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
Cordido F; Fernandez T; Martinez T; Peñalva A; Peinó R; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
[TBL] [Abstract][Full Text] [Related]
4. Evidence for an inhibitory effect of physiological levels of insulin on the growth hormone (GH) response to GH-releasing hormone in healthy subjects.
Lanzi R; Manzoni MF; Andreotti AC; Malighetti ME; Bianchi E; Sereni LP; Caumo A; Luzi L; Pontiroli AE
J Clin Endocrinol Metab; 1997 Jul; 82(7):2239-43. PubMed ID: 9215300
[TBL] [Abstract][Full Text] [Related]
5. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
[TBL] [Abstract][Full Text] [Related]
6. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
[TBL] [Abstract][Full Text] [Related]
7. Acute pharmacological reduction of plasma free fatty acids enhances the growth hormone (GH)-releasing hormone-mediated GH secretion in patients with Cushing's syndrome.
Leal-Cerro A; Jimenez LM; Astorga R; Fernandez-Lopez I; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1997 Sep; 82(9):3165-8. PubMed ID: 9284763
[TBL] [Abstract][Full Text] [Related]
8. Effect of acute pharmacological modulation of plasma free fatty acids on GH secretion in acromegalic patients.
Cordido F; Peñalva A; Martinez T; Casanueva FF; Dieguez C
Clin Endocrinol (Oxf); 2001 Apr; 54(4):509-13. PubMed ID: 11318787
[TBL] [Abstract][Full Text] [Related]
9. Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects.
Lanzi R; Luzi L; Caumo A; Andreotti AC; Manzoni MF; Malighetti ME; Sereni LP; Pontiroli AE
Metabolism; 1999 Sep; 48(9):1152-6. PubMed ID: 10484056
[TBL] [Abstract][Full Text] [Related]
10. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
Lee EJ; Nam SY; Kim KR; Lee HC; Cho JH; Nam MS; Song YD; Lim SK; Huh KB
J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
[TBL] [Abstract][Full Text] [Related]
11. Effect of acute reduction of free fatty acids by acipimox on growth hormone-releasing hormone-induced GH secretion in type 1 diabetic patients.
Alvarez P; Isidro L; Peinó R; Leal-Cerro A; Casanueva FF; Dieguez C; Cordido F
Clin Endocrinol (Oxf); 2003 Oct; 59(4):431-6. PubMed ID: 14510904
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone (GH) autofeedback on GH response to GH-releasing hormone. Role of free fatty acids and somatostatin.
Pontiroli AE; Lanzi R; Monti LD; Sandoli E; Pozza G
J Clin Endocrinol Metab; 1991 Feb; 72(2):492-5. PubMed ID: 1671389
[TBL] [Abstract][Full Text] [Related]
13. Effect of acipimox, a lipid lowering drug, on growth hormone (GH) response to GH-releasing hormone in normal subjects.
Pontiroli AE; Lanzi R; Monti LD; Pozza G
J Endocrinol Invest; 1990 Jun; 13(6):539-42. PubMed ID: 2258583
[TBL] [Abstract][Full Text] [Related]
14. Reduction of free fatty acids by acipimox enhances the growth hormone (GH) responses to GH-releasing peptide 2 in elderly men.
Van Dam PS; Smid HE; de Vries WR; Niesink M; Bolscher E; Waasdorp EJ; Dieguez C; Casanueva FF; Koppeschaar HP
J Clin Endocrinol Metab; 2000 Dec; 85(12):4706-11. PubMed ID: 11134132
[TBL] [Abstract][Full Text] [Related]
15. Acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid levels in hyperthyroidism.
Lee EJ; Kim KR; Lee HC; Cho JH; Nam MS; Nam SY; Song YD; Lim SK; Huh KB
Metabolism; 1995 Nov; 44(11):1509-12. PubMed ID: 7476342
[TBL] [Abstract][Full Text] [Related]
16. Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity.
Nam SY; Lee ; Kim KR; Lee HC; Nam MS; Cho JH; Huh KB
Metabolism; 1996 May; 45(5):594-7. PubMed ID: 8622602
[TBL] [Abstract][Full Text] [Related]
17. Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity.
Maccario M; Procopio M; Grottoli S; Oleandri SE; Boffano GM; Taliano M; Camanni F; Ghigo E
Metabolism; 1996 Mar; 45(3):342-6. PubMed ID: 8606641
[TBL] [Abstract][Full Text] [Related]
18. Free fatty acids block growth hormone (GH) releasing hormone-stimulated GH secretion in man directly at the pituitary.
Casanueva FF; Villanueva L; Dieguez C; Diaz Y; Cabranes JA; Szoke B; Scanlon MF; Schally AV; Fernandez-Cruz A
J Clin Endocrinol Metab; 1987 Oct; 65(4):634-42. PubMed ID: 2888782
[TBL] [Abstract][Full Text] [Related]
19. Pulsatile growth hormone secretion in patients with acromegaly and normal men: the effects of growth hormone-releasing hormone infusion.
Gelato MC; Oldfield E; Loriaux DL; Merriam GR
J Clin Endocrinol Metab; 1990 Sep; 71(3):585-90. PubMed ID: 2118536
[TBL] [Abstract][Full Text] [Related]
20. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
Gianotti L; Maccario M; Lanfranco F; Ramunni J; Di Vito L; Grottoli S; Muller EE; Ghigo E; Arvat E
J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]